2025-04-04 23:26:41
Latest Post
Sai Life Sciences sets up Peptide Research Center in India
Netweb Technologies Ltd receives PLI Incentive Under IT Hardware Scheme 2.0
BHEL signs contract for ± 800 kV, 6000 MW Bhadla-Fatehpur LCC HVDC Terminal Station along with AC Transmission at Bhadla and Fatehpur
DEE Development Engineers Limited receives order worth approx. Rs. 55 crores- SURATWWALA BUSINESS GROUP Ltd purchases new commercial office space
Stock Report
Lupin acquires Huminsulin from Lilly to Enhance Diabetes Portfolio
Posted On : 2024-12-30 22:44:52( TIMEZONE : IST )
Global pharma major Lupin Limited (Lupin) announced today the acquisition of Huminsulin® in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin range of products comprising of Insulin Human, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, through existing Distribution and Promotion Agreements with Lilly, India.
The Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children. Insulin treatment is the cornerstone of type 1 diabetes management and often becomes necessary over time in type 2 diabetes as the disease progresses. There is a significant Indian population affected with diabetes for both Type 1 and Type 2 Diabetes Mellitus, where Insulin Human is prescribed for management along with other concomitant therapies.
"This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide highquality, affordable health care to our patients. It reinforces our unwavering commitment to combating diabetes and providing comprehensive care," said Nilesh Gupta, Managing Director, Lupin.
Commenting on the acquisition, Rajeev Sibal, President - India Region Formulations, Lupin said, "Lupin has been at the forefront of providing holistic diabetes care to patients. This acquisition further strengthens our diabetes portfolio and enables us to offer a broad range of human insulin options to millions of patients, thereby helping them lead healthier lives."
Shares of Lupin Limited was last trading in BSE at Rs. 2309.65 as compared to the previous close of Rs. 2228.00. The total number of shares traded during the day was 72757 in over 7489 trades.
The stock hit an intraday high of Rs. 2328.40 and intraday low of 2227.00. The net turnover during the day was Rs. 165627689.00.
